- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08. | H.C. Wainwright stuft Journey Medical mit "Kaufen" ein - Rosacea-Medikament Emrosi als entscheidender Faktor | 7 | Investing.com Deutsch | ||
| 25.08. | H.C. Wainwright initiates Journey Medical stock with Buy rating on Emrosi potential | 2 | Investing.com | ||
| 20.08. | Journey Medical setzt auf Rosacea-Mittel Imrozi für Profitabilitätswende | 4 | Investing.com Deutsch | ||
| 13.08. | Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples | 4 | Seeking Alpha | ||
| 12.08. | Journey Medical Corp - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 12.08. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 12.08. | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 503 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen | |
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 11.08. | Examining the Future: Journey Medical's Earnings Outlook | 2 | Benzinga.com | ||
| 07.08. | Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 | 3 | GlobeNewswire (USA) | ||
| 05.08. | Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 | 1 | GlobeNewswire (USA) | ||
| 14.07. | Journey Medical Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 14.07. | Journey Medical's rosacea treatment reaches 65% commercial coverage | 2 | Investing.com | ||
| 14.07. | Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi | 2 | GlobeNewswire (USA) | ||
| 24.06. | Journey Medical to join Russell 2000 and 3000 indexes | 3 | Investing.com | ||
| 24.06. | Journey Medical Corporation: Journey Medical to Join Russell 2000 and Russell 3000 Indexes | 1 | GlobeNewswire (USA) | ||
| 24.06. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | Journey Medicals Rosacea-Medikament zeigt Wirksamkeit unabhängig vom Gewicht | 1 | Investing.com Deutsch | ||
| 09.06. | Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV | 2 | GlobeNewswire (USA) | ||
| 15.05. | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,105 | +1,05 % | Lohnt hier der Einstieg? NetraMark, Novartis, Pfizer | Aufgrund der globalen Nachfrage nach Gesundheitsdienstleistungen und technologischen Erneuerungen kann eine Investition in den Gesundheitssektor besonders lukrativ sein. Der demografische Wandel in... ► Artikel lesen | |
| GILEAD SCIENCES | 98,39 | -0,15 % | Aktienmarkt: Kurs der Aktie von Gilead Sciences im Plus (98,5365 €) | Das Wertpapier von Gilead Sciences notiert heute fester. Zuletzt zahlten Investoren für das Papier 115,47 US-Dollar. Die Aktie von Gilead Sciences verzeichnet gegenwärtig einen Wertanstieg von 2,39... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 338,15 | +0,62 % | Is Vertex Pharmaceuticals Stock Underperforming the S&P 500? | ||
| EYEPOINT PHARMACEUTICALS | 12,065 | +3,87 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| ROCKET LAB | 40,200 | -0,99 % | Wochenrückblick 36/2025: Meine stärksten Kurstreiber im Depot waren Broadcom, Almonty, AeroVironment, Viper Energy. Und auch meine Neuerwerbungen Rocket Lab und Amphenol spielen jetzt eine gewichtige Rolle... | Die Top-Werte meines Investmentdepots veröffentliche ich jeweils zum Quartalsende in meinen Investor-Updates und meine Beobachtungsliste aktualisiere ich wöchentlich.Ergänzend gebe ich heute eine kurze... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 6,300 | -0,79 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025 | Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial... ► Artikel lesen | |
| OPKO HEALTH | 1,206 | +0,22 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 138,00 | -0,72 % | Oppenheimer raises Ligand Pharma stock price target to $190 on lower WACC | ||
| JAZZ PHARMACEUTICALS | 108,70 | -1,63 % | Jazz Pharmaceuticals plc: Modeyso (dordaviprone) Included in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma | Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the United States
For U.S. media and investors... ► Artikel lesen | |
| UNITED THERAPEUTICS | 340,10 | +1,31 % | Aktien New York: Steigende US-Zinsen und schwache Techwerte belasten | NEW YORK (dpa-AFX) - Steigende Zinsen an den Kapitalmärkten und teils stark fallende Technologieaktien haben am Dienstag die großen US-Aktienindizes belastet. Der Leitindex Dow Jones Industrial fiel... ► Artikel lesen | |
| ROYALTY PHARMA | 30,170 | -0,89 % | Royalty Pharma Prices $2 Bln Offering Of Senior Unsecured Notes | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) announced the pricing of a $2.0 billion offering of senior unsecured notes. The issuance includes $600 million of 4.450% Notes due 2031, $900... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 17,360 | +1,70 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 45,480 | -1,49 % | BridgeBio stock maintains Buy rating at H.C. Wainwright on positive encaleret data | ||
| TG THERAPEUTICS | 27,235 | -1,05 % | TG Therapeutics, Inc.: TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment | NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has commenced in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy)... ► Artikel lesen | |
| AVADEL PHARMACEUTICALS | 13,000 | -0,76 % | Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd | - Expands Avadel's pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia - - Initial pharmacokinetic (PK) and comparative... ► Artikel lesen |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 7,245 Euro und damit +3,35 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.